Evidence map›Paper›PMID 34765298›Full record

ArticleAmerican journal of cancer research2021

Sensitization of breast cancer to Herceptin by redox active nanoparticles.

Jie Hao, Lin Yu, Heng Lu, Tamil S Sakthivel, Sudipta Seal, Bolin Liu, Jihe Zhao

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Nanoceria: an innovative strategy for cancer treatment.Cellular and molecular life sciences : CMLS · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jie HaoBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando FL 32827, USA.
Lin YuBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando FL 32827, USA.
Heng LuBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando FL 32827, USA.
Tamil S SakthivelDepartment of Material Science and Engineering, Advanced Materials Processing and Analysis Center, Nanoscience Technology Center, Biionix Cluster, College of Medicine, University of Central Florida Orlando, FL 32816, USA.
Sudipta SealDepartment of Material Science and Engineering, Advanced Materials Processing and Analysis Center, Nanoscience Technology Center, Biionix Cluster, College of Medicine, University of Central Florida Orlando, FL 32816, USA.
Bolin LiuDepartment of Genetics, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center New Orleans, LA 70112, USA.
Jihe ZhaoBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando FL 32827, USA.
Florida College · USLouisiana State University Health Sciences Center New Orleans · USUniversity of Central Florida · US

Funding

KLF8 Regulation of EMT Tumor MetastasisR01CA132977 · NCI · UNIVERSITY OF CENTRAL FLORIDA · PI ZHAO, JIHE · 2009 to 2014
$1.3M
NCI NIH HHS R01 CA132977
6 · The paper itself

Abstract

Herceptin-resistant tumor relapse remains a major clinical issue responsible for the poor prognosis of HER2

Indexed as

Breast cancercerium oxide nanoparticlesHER2Herceptin resistance

Identifiers

PMID34765298
PMCPMC8569362
OpenAlexW3214264070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.